SPY311.36-0.82 -0.26%
DIA263.33+0.16 0.06%
IXIC9,615.81-67.10 -0.69%
News
EDIT
--
0.00%
--
Edited Transcript of EDIT earnings conference call or presentation 7-May-20 12:00pm GMT
Thomson Reuters StreetEvents · 16h ago
Why Editas Medicine Is Now the CRISPR Stock to Really Watch
Motley Fool · 1d ago
Editas (EDIT) Moves to Buy: Rationale Behind the Upgrade
Zacks · 6d ago
4 Promising Stocks to Own That You Probably Forgot About
Motley Fool · 05/23 12:28
Here's Why Editas Could Beat Intellia to a CRISPR Therapy
Motley Fool · 05/22 12:39
Beam Therapeutics Taking Novel Approach to Gene Therapy
GuruFocus.com · 05/18 23:21
Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies
GlobeNewswire · 05/15 14:20
Editas Medicines Reports Preclinical Data Support Use Of CRISPR-Cas12a To Edit Induced Pluripotent Stem Cells For Development Of Engineered Cell Immunotherapies
Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study evaluating multi-gene knockout and transgene knock-in using its proprietary engineered
Benzinga · 05/15 13:22
Morgan Stanley Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $27
Morgan Stanley maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and lowers the price target from $30 to $27.
Benzinga · 05/11 13:12
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Simply Wall St. · 05/10 14:28
Editas' (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y
Zacks · 05/08 17:38
Editas Medicine, Inc. (EDIT) Q1 2020 Earnings Call Transcript
MotleyFool.com · 05/08 04:00
Editas Medicine, Inc. 2020 Q1 - Results - Earnings Call Presentation
Seeking Alpha - Article · 05/07 18:27
Editas Medicine EPS beats by $0.10, misses on revenue
Editas Medicine (NASDAQ:EDIT): Q1 GAAP EPS of -$0.69 beats by $0.10. Revenue of $5.72M (+176.3% Y/Y) misses by $1M. Shares +0.6% PM. Press Release
seekingalpha · 05/07 16:03
Editas Medicine (EDIT) Reports Q1 Loss, Lags Revenue Estimates
Zacks · 05/07 15:15
Editas Medicine, Inc. (EDIT) CEO Cynthia Collins on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/07 14:11
Editas Medicine Announces First Quarter 2020 Results and Update
GlobeNewswire · 05/07 12:00
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.)
Benzinga · 05/07 11:42
Editas Medicine Q1 EPS $(0.690) Beats $(0.770) Estimate, Sales $5.723M Miss $7.020M Estimate
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.690) per share which beat the analyst consensus estimate of $(0.770) by 10.39 percent. This is a 15 percent decrease over losses of $(0.600) per share from
Benzinga · 05/07 11:27
Notable earnings before Thursday's open
Seeking Alpha - Article · 05/06 21:30